Investor overview
A powerful, scalable platform.
Supporting a large, growing and badly under-served diagnostic market, PROMEDX is excited to be shaping the scientific landscape.
De-risked science
Two decades of peer-reviewed validation, anchored by a prospective multi-center NIH outcome trial.
Capital-light model
Software analysis of a standard, reimbursable scan: no new hardware in the clinic.
Recurring clinical use
Staging and longitudinal monitoring drive repeat utilization across the disease course.
Contact